2160 — MicroPort CardioFlow Medtech Income Statement
0.000.00%
- HK$3.02bn
- HK$3.43bn
- $57.04m
Annual income statement for MicroPort CardioFlow Medtech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | R2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | PRESS | PRESS |
| Standards: | IFRS | IFRS | IFRS | — | — |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Revenue | |||||
| Total Revenue | 31.1 | 37.3 | 47.5 | 50.8 | 57 |
| Cost of Revenue | |||||
| Gross Profit | 18.4 | 24.1 | 32.5 | 35.3 | 37.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 55.8 | 93.3 | 103 | 48.1 | 66.3 |
| Operating Profit | -24.7 | -56 | -55.8 | 2.73 | -9.22 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -28.3 | -67.1 | -65.5 | -6.5 | -18 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -28.4 | -67.5 | -66.6 | -7.49 | -18.8 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -28.4 | -67.5 | -66.6 | -6.95 | -18.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -28.4 | -67.5 | -66.6 | -6.95 | -18.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.06 | -0.133 | -0.125 | -0.031 | -0.043 |